You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Targeted Therapy for Medullary Thyroid Cancer: A Review
|
|---|---|
| Published in |
Frontiers in oncology, October 2017
|
| DOI | 10.3389/fonc.2017.00238 |
| Pubmed ID | |
| Authors |
S. R. Priya, Chandra Shekhar Dravid, Raghunadharao Digumarti, Mitali Dandekar |
| Abstract |
Medullary thyroid cancers (MTCs) constitute between 2 and 5% of all thyroid cancers. The 10-year overall survival (OS) rate of patients with localized disease is around 95% while that of patients with regional stage disease is about 75%. Only 20% of patients with distant metastases at diagnosis survive 10 years which is significantly lower than for differentiated thyroid cancers. Cases with regional metastases at presentation have high recurrence rates. Adjuvant external radiation confers local control but not improved OS. The management of residual, recurrent, or metastatic disease till a few years ago was re-surgery with local measures such as radiation. Chemotherapy was used with marginal benefit. The development of targeted therapy has brought in a major advantage in management of such patients. Two drugs-vandetanib and cabozantinib-have been approved for use in progressive or metastatic MTC. In addition, several drugs acting on other steps of the molecular pathway are being investigated with promising results. Targeted radionuclide therapy also provides an effective treatment option with good quality of life. This review covers the rationale of targeted therapy for MTC, present treatment options, drugs and methods under investigation, as well as an outline of the adverse effects and their management. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 20% |
| Spain | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 16% |
| Researcher | 8 | 11% |
| Student > Master | 7 | 9% |
| Student > Ph. D. Student | 6 | 8% |
| Student > Doctoral Student | 5 | 7% |
| Other | 10 | 14% |
| Unknown | 26 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 31% |
| Biochemistry, Genetics and Molecular Biology | 12 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Agricultural and Biological Sciences | 3 | 4% |
| Nursing and Health Professions | 1 | 1% |
| Other | 5 | 7% |
| Unknown | 24 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2023.
All research outputs
#1,465,080
of 25,382,440 outputs
Outputs from Frontiers in oncology
#258
of 22,428 outputs
Outputs of similar age
#29,336
of 332,159 outputs
Outputs of similar age from Frontiers in oncology
#6
of 96 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,428 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,159 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.